The Sex Issue - The Burrill Report

More documents

Recommendations

Info

The BioExec Institute 2008 The inside story and network to BioPharma Register now www.deloitte.com/us/bioexec2008/tjols “I scoured the Web sites of major business schools in search of a program that would provide an overview of the biopharma industry. The BioExec program was the only program I came across, and it is essentially exactly what I was looking for in an executive program.” Ruediger Schulze Marketing Director of Neurology Germany, Johnson & Johnson The BioExec Institute is an executive program delivered by leading industry experts to director and VP-level management who are searching for the keys to managing business trade-offs within a highly regulated and competitive industry. Alongside BioExec Institute faculty and alumni, attendees will participate in a six-day interactive program [three modules of two days each], including three evening networking receptions. Participants will have unique opportunities to debate the strategies and tactics of business leadership within BioPharma and will complete the program with invaluable insight and powerful networks to deliver bottom line value in this growing industry. b The Journal of Life Sciences november/december 2008
Agenda October 8 & 9, 2008 Module A Creating Value The Haas School of Business, UC Berkeley, Berkeley, California November 3 & 4, 2008 Module B Managing Value Mission Bay Conference Center at UCSF, San Francisco, California December 8 & 9, 2008 Module C Growing Value The Haas School of Business, UC Berkeley, Berkeley, California Partial list of confirmed and invited faculty Martin Babler, Entrepreneur; Former Vice President, Immunology Sales and Marketing, Genentech, Inc. G. Steve Burrill, CEO, Burrill & Company R.T. (Terry) Hisey, Vice Chairman and U.S. Life Sciences Leader, Deloitte & Touche USA LLP Barbara Ryan, Chief Analyst, Deutsche Bank David A. Kessler, M.D., Dean & Vice Chancellor for Medical Affairs, UCSF School of Medicine, and former Commissioner of the FDA Gareth Morgan, Executive Director, Central Clinical Operations, Bristol-Myers Squibb Eric J. Patzer, Ph.D., President and CEO, Aridis Pharmaceuticals, LLC Steve Buckanavage, Vice President, Global Marketing, Oncology & Infection Therapy Area, AstraZeneca Pharmaceuticals Chris Horan, Vice President, Planning, Distribution and Logistics, Genentech, Inc. Janet L. (Lucy) Rose, Managing Director, Life Sciences Regulatory & Capital Markets Consulting, Deloitte & Touche LLP and former Director of the Office of Training and Communications and DDMAC, CDER, FDA For more information or to register Visit www.deloitte.com/us/bioexec2008/tjols or contact: • Within the U.S.: Jennie McGihon, Deloitte Services LP, +1 202 220 2783 or jemcgihon@deloitte.com or Chelsea Hewitt, Prescience International, +1 408 960 2316 or chelsea@prescienceintl.com • International: Aurélie Gaudin, Prescience International, at +33 681 1040 96 or aurelie@prescienceintl.com Limited enrollment. Register early to receive a $1,000 discount and to guarantee your spot. Deloitte refers to one or more of Deloitte Touche Tohmatsu, a Swiss Verein, its member firms, and their respective subsidiaries and affiliates. As a Swiss Verein (association), neither Deloitte Touche Tohmatsu nor any of its member firms have any liability for each other’s acts or omissions. Each of the member firms is a separate and independent legal entity operating under the names “Deloitte,” “Deloitte & Touche,” “Deloitte Touche Tohmatsu,” or other related names. Services are provided by the member firms or their subsidiaries or affiliates and not by the Deloitte Touche Tohmatsu Verein. Deloitte & Touche USA LLP is the U.S. member firm of Deloitte Touche Tohmatsu. In the United States, services are provided by the subsidiaries of Deloitte & Touche USA LLP (Deloitte & Touche LLP, Deloitte Consulting LLP, Deloitte Financial Advisory Services LLP, Deloitte Tax LLP, and their subsidiaries), and not by Deloitte & Touche USA LLP. 1 The Journal of Life Sciences Copyright © 2008 Deloitte Development LLC. All rights reserved. november/december 2008
Page 1: NOVEMBER / DECEMBER 2008 The Sex Is
Page 5 and 6: 62 13 34 58 26 34 DEPARTMENTS 4 Pub
Page 7 and 8: A better life Global lea
Page 9 and 10: The Journal of Life Sciences 7 nove
Page 11 and 12: • • • • • • •
Page 13 and 14: Fighting life-threatening diseases.
Page 15 and 16: in sample form, in such instances,
Page 17 and 18: generally are not daily coffee drin
Page 19 and 20: ers are increasingly being priced o
Page 21 and 22: courtesy of diedrichharmon built-in
Page 23 and 24: Happy Customers Sexual satisfaction
Page 25 and 26: Global Coverage Dek: Percent of the
Page 27 and 28: Leadership. Education. Action. CHI
Page 29 and 30: lete,” says Newquist, who rode on
Page 31 and 32: the National Coalition for Cancer S
Page 33 and 34: Job well done: Cancer survivors Jus
Page 35 and 36: 3 3 The Journal of Life Sciences no
Page 37 and 38: dietary supplements are” says Dav
Page 39 and 40: Topinama of Brazil, who encourage p
Page 41 and 42: The medical establishment generally
Page 43 and 44: Stimulating the Appetite The pharma
Page 45 and 46: the various aspects of the disorder
Page 47 and 48: an FDA reluctant to approve new the
Page 49 and 50: When one of Hilario Aguirre’s thr
Page 51 and 52: daniel s. levine The reality is, ma
Page 53 and 54:
The clinics seem to be responding t
Page 55 and 56:
Even clinics developed with the bac
Page 57 and 58:
into a commercial one. Although Aco
Page 59 and 60:
ment, but at the low valuation it d
Page 61 and 62:
As perhaps one of the few, if only,
Page 63 and 64:
grad, has an athletic, all-American
Page 65 and 66:
test subjects in modern medical sci
Page 67 and 68:
Q: How did you first get into this?
Page 69:
MORE ccelerate ioinformatics ommuni
show all

The Sex Issue - The Burrill Report

Create successful ePaper yourself

Delete template?

Save as template?